Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jan 27, 2021- Sales of $10.7 billion, including $2.4 billion of COVID-19 diagnostic testing-related sales- Sales growth of 28.7 percent; organic sales growth of 28.4 percent- GAAP diluted EPS from continuing operations growth of 103.4 percent; adjusted diluted EPS growth of 52.6 percent- Delivered more than 300 million COVID-19 diagnostics tests in fourth quarter 2020- R&D pipeline continues to be highly productive, delivering ground-breaking innovations and a steady cadence of important new products across all business areas- Issues 2021 EPS growth forecast of more than 35 percent- Jan 26, 2021- Panbio™ COVID-19 Ag Rapid Test Device supports mass testing in congregate populations of people (mass screening) who are asymptomatic- Frequent screening of asymptomatic and symptomatic people helps restore a sense of safety at workplaces, schools, travel and recreational settings, and other places where people gather in large numbers- Test is approved for use with a patient-friendly and minimally invasive nasal swab; patients can self-administer sample collection under a healthcare professional's supervision- Panbio COVID-19 Ag delivers results in as early as 15 minutes with no instrumentation, using proven Abbott lateral flow technology- Test performance in clinical study demonstrated 93.8% sensitivity and 100.0% specificity in asymptomatic people with high viral loads- Along with the test, Abbott will offer complementary digital solutions: the NAVICA™ mobile app to allow people to display negative results for proof of testing and Sympheos™ for surveillance management to understand epidemiological trends- Since August 2020 to date, Abbott has shipped 200 million Panbio rapid antigen tests to 120 countries worldwide
- Jan 20, 2021- New national reimbursement enables access to transcatheter mitral valve repair procedures with MitraClip for people with secondary mitral regurgitation, significantly expanding the eligible patient population
- Jan 14, 2021- New app will allow patients to record their pain relief during the device trial period with spinal cord stimulation or dorsal root ganglion therapy, simplify reporting outcomes and connect patients to physicians who have real-time access to this data- NeuroSphere myPath will be available in the Apple App Store in the coming weeks and will be compatible with the latest iOS operating system
- Jan 12, 2021- Abbott will complete the U.S. government order for 150 million BinaxNOW COVID-19 tests this week and will supply 30 million additional tests through March via a new government order- Company is in final stages of completing its self-funded capacity expansion across U.S. manufacturing sites- Abbott has the most advanced and comprehensive COVID-19 rapid test portfolio available today, including ID NOW, BinaxNOW, the BinaxNOW at-home test and the NAVICA app- Workplaces, universities, schools and other qualified organizations that need frequent and affordable testing can now directly procure BinaxNOW tests from Abbott